Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30568030 | 1.00 | LMNA (0.39) | LMNATP53HTTMDM2P2RX7 | |
| SCHEMBL27882050 | 0.85 | KCNH2 (0.43) | LMNATP53HTTP2RX7PDE2A | |
| SCHEMBL10553016 | 0.83 | MDM2 (0.41) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL420958 | 0.83 | LMNA (0.42) | LMNATP53HTTMDM2P2RX7 | |
| SCHEMBL17061753 | 0.81 | LMNA (0.41) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL23212834 | 0.79 | PDE2A (0.59) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL17215540 | 0.79 | PDE2A (0.59) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL22855048 | 0.79 | LMNA (0.64) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL21239903 | 0.79 | LMNA (0.39) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL17069211 | 0.79 | DPP4 (0.40) | LMNATP53HTTMDM2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| CN-111936503-A | Oxazin monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | disclosed |
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| CN-102256983-A | Spirooxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2011-11-23 | — | — | CN | disclosed |
| CN-102153562-A | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC | 2011-08-17 | — | — | CN | disclosed |
| CN-101605757-A | Be used for (indoles-4-yl) of obesity treatment-or (indoles-5-yl)-piperazinyl methanone derivatives | HOFFMANN LA ROCHE (CH) | 2009-12-16 | — | — | CN | disclosed |
| CN-101184761-A | Spiro-indolone compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-05-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | LMNA 381/4885TP53 4672/4885HTT 4359/4885 |
| US-20180118708-A1 | CYCLIC COMPOUND | TLR4, TLR3, TLR9 | LMNA 3947/4885TP53 562/4885HTT 3910/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | LMNA 381/4885TP53 4672/4885HTT 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.